SEC Form 4

FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

()										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

I

		•	Filed pursuant to Section 16(a) of the Securities Exchange Act of 193	34		Estimated ave hours per resp	0	0.5
1. Name and Addro Kullman Ello		Person*	2. Issuer Name and Ticker or Trading Symbol <u>AMGEN INC</u> [AMGN]	(Check a	onship of F II applicab Director		on(s) to Issuer 10% Owner	
(Last) ONE AMGEN	(First) CENTER DRI	(Middle) VE	3. Date of Earliest Transaction (Month/Day/Year) 05/05/2020		Officer (giv below)	ve title	Other (specify below)	У
(Street) THOUSAND OAKS (City)	CA (State)	91320 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line) X	Form filed	by One Repor	(Check Applica rting Person One Reporting	
		Table I - Non-De	rivative Securities Acquired, Disposed of, or Bene	eficially C	Owned			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code V		v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11511.4)
Common Stock	05/05/2020		Α		977.1559	Α	\$ <mark>0</mark>	6,380 .1559 ⁽¹⁾⁽²⁾	D	

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the deferral schedule.

2. These shares include 252 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.



05/07/2020 Attorney-in-Fact for Ms. Kullman

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.